BRAF mutation analysis is currently not so common in CRC patients, but multigene testing including KRAS, NRAS, and BRAF by luminex‐based multiplex assay will be available soon in Japan, and the European Society for Medical Oncology consensus guidelines recommend BRAF testing as grade B 28. Here, NRAS is linked to colorectal carcinoma.